Hormonal
Concomitant use of linaclotide is associated with significantly greater weight loss in patients taking semaglutide, whereas diabetes mellitus and dulaglutide use are associated with reduced efficacy.
If you are taking semaglutide, your other medications matter. Taking linaclotide (for constipation/IBS) is associated with better weight loss results, while taking diabetes medications like dulaglutide or metformin, or having a diabetes diagnosis, is associated with less weight loss. This suggests that your specific health profile and other drugs significantly influence semaglutide's effectiveness.
Adjusted ORs of achieving 10% weight loss 52 weeks after semaglutide exposure... Linaclotide 14.95 (2.54, 87.97)... Dulaglutide 0.26 (0.09, 0.75)... Diabetes mellitus 0.44 (0.22, 0.87).
Why this rating
Derived from machine learning feature importance (SHAP) and logistic regression on real-world EHR data.
Source
Medications and conditions associated with weight loss in patients prescribed semaglutide based on real‐world data
William C. Powell et al. · Obesity · 2023
DOI 10.1002/oby.23859
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →